Gray et al. reported biomarker analysis from the FLAURA trial, demonstrating the utility of the cobas EGFR mutation tissue and plasma testing [53] to aid selection of patients with EGFRm advanced NSCLC for first-line osimertinib treatment [31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.